Cargando…
A systematic review of real-world evidence of the management of macular oedema secondary to branch retinal vein occlusion
This review assessed the real-world evidence of the management of macular oedema secondary to branch retinal vein occlusion (BRVO). A meta-analysis of 2530 eyes from 48 real-world studies of therapies for macular oedema secondary to BRVO was conducted. Baseline characteristics, visual, anatomical an...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7608462/ https://www.ncbi.nlm.nih.gov/pubmed/32313172 http://dx.doi.org/10.1038/s41433-020-0861-9 |
_version_ | 1783604844964085760 |
---|---|
author | Ang, Juan Lyn Ah-Moye, Sarah Kim, Leah N. Nguyen, Vuong Hunt, Adrian Barthelmes, Daniel Gillies, Mark C. Mehta, Hemal |
author_facet | Ang, Juan Lyn Ah-Moye, Sarah Kim, Leah N. Nguyen, Vuong Hunt, Adrian Barthelmes, Daniel Gillies, Mark C. Mehta, Hemal |
author_sort | Ang, Juan Lyn |
collection | PubMed |
description | This review assessed the real-world evidence of the management of macular oedema secondary to branch retinal vein occlusion (BRVO). A meta-analysis of 2530 eyes from 48 real-world studies of therapies for macular oedema secondary to BRVO was conducted. Baseline characteristics, visual, anatomical and safety outcomes were recorded. The weighted mean and weighted estimates from random-effects models were calculated for visual acuity (VA) and central subfield thickness (CST) changes at 6, 12 and 24 months. Primary outcome was change in VA (logMAR letters) at 12 months. Study quality was assessed using the quality appraisal checklist for case series developed by Institute of Health Economics. The mean baseline VA for the pooled data was 54.0 (51.5, 56.5) letters and the mean baseline CST was 501.3 (483.5, 519.1) µm. The random-effects estimate for mean (95% CI) change in VA was 14.6 (12.5, 16.7) letters at 12 months (n = 1727). The random-effects estimate for mean (95% CI) change in CST was −181.7 (−230.7, −132.7) µm at 12 months (n = 1325). The quality of studies varied considerably. Ocular and systemic adverse events were discussed in 79% and 42% of treatment arms respectively, with possible under-reporting. Visual and anatomical gains achieved in the real-world for anti-VEGF therapy were not as impressive as seminal RCTs, possibly due to reduced injection frequency in the real world and differences in baseline characteristics. There is an urgent need for consensus on the minimum efficacy, treatment burden and safety data to collect to strengthen the real-world evidence base. |
format | Online Article Text |
id | pubmed-7608462 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-76084622020-11-05 A systematic review of real-world evidence of the management of macular oedema secondary to branch retinal vein occlusion Ang, Juan Lyn Ah-Moye, Sarah Kim, Leah N. Nguyen, Vuong Hunt, Adrian Barthelmes, Daniel Gillies, Mark C. Mehta, Hemal Eye (Lond) Review Article This review assessed the real-world evidence of the management of macular oedema secondary to branch retinal vein occlusion (BRVO). A meta-analysis of 2530 eyes from 48 real-world studies of therapies for macular oedema secondary to BRVO was conducted. Baseline characteristics, visual, anatomical and safety outcomes were recorded. The weighted mean and weighted estimates from random-effects models were calculated for visual acuity (VA) and central subfield thickness (CST) changes at 6, 12 and 24 months. Primary outcome was change in VA (logMAR letters) at 12 months. Study quality was assessed using the quality appraisal checklist for case series developed by Institute of Health Economics. The mean baseline VA for the pooled data was 54.0 (51.5, 56.5) letters and the mean baseline CST was 501.3 (483.5, 519.1) µm. The random-effects estimate for mean (95% CI) change in VA was 14.6 (12.5, 16.7) letters at 12 months (n = 1727). The random-effects estimate for mean (95% CI) change in CST was −181.7 (−230.7, −132.7) µm at 12 months (n = 1325). The quality of studies varied considerably. Ocular and systemic adverse events were discussed in 79% and 42% of treatment arms respectively, with possible under-reporting. Visual and anatomical gains achieved in the real-world for anti-VEGF therapy were not as impressive as seminal RCTs, possibly due to reduced injection frequency in the real world and differences in baseline characteristics. There is an urgent need for consensus on the minimum efficacy, treatment burden and safety data to collect to strengthen the real-world evidence base. Nature Publishing Group UK 2020-04-20 2020-10 /pmc/articles/PMC7608462/ /pubmed/32313172 http://dx.doi.org/10.1038/s41433-020-0861-9 Text en © The Author(s), under exclusive licence to The Royal College of Ophthalmologists 2020 |
spellingShingle | Review Article Ang, Juan Lyn Ah-Moye, Sarah Kim, Leah N. Nguyen, Vuong Hunt, Adrian Barthelmes, Daniel Gillies, Mark C. Mehta, Hemal A systematic review of real-world evidence of the management of macular oedema secondary to branch retinal vein occlusion |
title | A systematic review of real-world evidence of the management of macular oedema secondary to branch retinal vein occlusion |
title_full | A systematic review of real-world evidence of the management of macular oedema secondary to branch retinal vein occlusion |
title_fullStr | A systematic review of real-world evidence of the management of macular oedema secondary to branch retinal vein occlusion |
title_full_unstemmed | A systematic review of real-world evidence of the management of macular oedema secondary to branch retinal vein occlusion |
title_short | A systematic review of real-world evidence of the management of macular oedema secondary to branch retinal vein occlusion |
title_sort | systematic review of real-world evidence of the management of macular oedema secondary to branch retinal vein occlusion |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7608462/ https://www.ncbi.nlm.nih.gov/pubmed/32313172 http://dx.doi.org/10.1038/s41433-020-0861-9 |
work_keys_str_mv | AT angjuanlyn asystematicreviewofrealworldevidenceofthemanagementofmacularoedemasecondarytobranchretinalveinocclusion AT ahmoyesarah asystematicreviewofrealworldevidenceofthemanagementofmacularoedemasecondarytobranchretinalveinocclusion AT kimleahn asystematicreviewofrealworldevidenceofthemanagementofmacularoedemasecondarytobranchretinalveinocclusion AT nguyenvuong asystematicreviewofrealworldevidenceofthemanagementofmacularoedemasecondarytobranchretinalveinocclusion AT huntadrian asystematicreviewofrealworldevidenceofthemanagementofmacularoedemasecondarytobranchretinalveinocclusion AT barthelmesdaniel asystematicreviewofrealworldevidenceofthemanagementofmacularoedemasecondarytobranchretinalveinocclusion AT gilliesmarkc asystematicreviewofrealworldevidenceofthemanagementofmacularoedemasecondarytobranchretinalveinocclusion AT mehtahemal asystematicreviewofrealworldevidenceofthemanagementofmacularoedemasecondarytobranchretinalveinocclusion AT angjuanlyn systematicreviewofrealworldevidenceofthemanagementofmacularoedemasecondarytobranchretinalveinocclusion AT ahmoyesarah systematicreviewofrealworldevidenceofthemanagementofmacularoedemasecondarytobranchretinalveinocclusion AT kimleahn systematicreviewofrealworldevidenceofthemanagementofmacularoedemasecondarytobranchretinalveinocclusion AT nguyenvuong systematicreviewofrealworldevidenceofthemanagementofmacularoedemasecondarytobranchretinalveinocclusion AT huntadrian systematicreviewofrealworldevidenceofthemanagementofmacularoedemasecondarytobranchretinalveinocclusion AT barthelmesdaniel systematicreviewofrealworldevidenceofthemanagementofmacularoedemasecondarytobranchretinalveinocclusion AT gilliesmarkc systematicreviewofrealworldevidenceofthemanagementofmacularoedemasecondarytobranchretinalveinocclusion AT mehtahemal systematicreviewofrealworldevidenceofthemanagementofmacularoedemasecondarytobranchretinalveinocclusion |